- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00084513
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
Phase I of Trastuzumab and Imatinib Mesylate (Gleevec®, Formerly Known as STI-571) in Patients With Recurrent or Metastatic Her-2/Neu Expressing Cancer
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Giving trastuzumab together with imatinib mesylate may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with trastuzumab in treating patients with recurrent or metastatic HER2/neu-expressing (producing) cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of imatinib mesylate when administered with trastuzumab (Herceptin®) in patients with recurrent or metastatic HER2/neu-overexpressing cancer.
- Determine response in patients treated with this regimen.
Secondary
- Correlate the number of circulating tumor cells with radiographic imaging in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of imatinib mesylate.
Patients receive trastuzumab (Herceptin®) IV over 90 minutes on day 1 and oral imatinib mesylate once or twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: Approximately 9-18 patients will be accrued for this study.
Type d'étude
Inscription (Anticipé)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19111-2497
- Fox Chase Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed cancer that overexpresses HER2/neu, measured 3+ by immunohistochemistry or positive by fluorescence in situ hybridization
- Recurrent or metastatic disease
Meets 1 of the following criteria for measurable or evaluable disease:
- Unidimensionally measurable disease at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- Evaluable disease, defined as a lesion on physical examination or imaging study that can be assessed as to changes in size but cannot be clearly measured in 1 dimension (e.g., pleural effusions, ascites, or bone disease)
No carcinomatous meningitis or untreated/uncontrolled metastatic brain parenchymal disease
- Prior controlled brain parenchymal disease allowed provided at least 8 weeks since prior therapy AND no symptomatic progression off corticosteroids
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- ALT and AST ≤ 2.0 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.0 times ULN
- Bilirubin ≤ 1.3 mg/dL
- No known chronic liver disease (i.e., chronic active hepatitis or cirrhosis)
Renal
- Creatinine ≤ 2.0 mg/dL
Cardiovascular
- Ejection fraction ≥ lower limit of normal by MUGA
- No uncontrolled or significant cardiovascular disease
- No myocardial infarction within the past 6 months
- No ischemic heart disease requiring medication
- No congestive heart failure
Pulmonary
- No uncontrolled or significant pulmonary disease
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception during and for 3 months after study participation
- No active unresolved infection
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Prior trastuzumab (Herceptin®) allowed
- No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) to support blood counts
- No other concurrent anticancer biologic agents
Chemotherapy
- Prior chemotherapy for metastatic disease allowed
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
- No concurrent anticancer chemotherapy
Endocrine therapy
- See Disease Characteristics
Radiotherapy
- At least 4 weeks since prior radiotherapy and recovered
Surgery
- More than 2 weeks since prior major surgery
Other
- At least 7 days since prior antibiotics
- No concurrent parenteral antibiotics
- No other concurrent anticancer agents
- No other concurrent investigational drugs
No concurrent therapeutic anticoagulation with warfarin
- Concurrent mini-dose warfarin (1 mg/day) for prophylaxis of central venous catheter thrombosis allowed
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
---|
Maximum tolerated dose (MTD) of imatinib mesylate given concurrently with trastuzumab (Herceptin®) as measured by CTC v 3.0 at course 1
|
Response as measured by RECIST criteria every 9 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
---|
Circulating tumor cells in blood as measured by Immunicom Cell PrepTM at baseline, every 3 weeks until week 9, and then with each disease re-evaluation
|
Phosphorylation status of AKT, extracellular signal-regulated kinase (ERK), and KIT as measured by western blot and/or immunohistochemistry at baseline and week 9
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000365451
- P30CA006927 (Subvention/contrat des NIH des États-Unis)
- FCCC-03041
- NOVARTIS-FCCC-03041
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur mésylate d'imatinib
-
Seoul St. Mary's HospitalNovartisInconnueLa leucémie myéloïde chroniqueCorée, République de
-
University of Auckland, New ZealandLeukaemia & Blood Cancer New ZealandActif, ne recrute pasLa leucémie myéloïde chroniqueNouvelle-Zélande
-
Institut BergoniéNovartisRésiliéLeucémie, myéloïde, phase chroniqueFrance
-
AllerganComplétéHypertension oculaire | Glaucome à angle ouvertCorée, République de
-
Northwestern UniversityAllerganComplétéPression intraocculaire | Arrêt de la croissance des onglesÉtats-Unis
-
Medical University of SilesiaCentrum Medyczne Andrzej BożekPas encore de recrutementAsthme, allergique
-
New Mexico Cancer Care AllianceRetiréLeucémie myéloïde chroniqueÉtats-Unis
-
Mansoura UniversityComplétéLMC, phase chronique | Leucémie myéloïde chronique, BCR-ABL PositifEgypte
-
PfizerRecrutementRectocolite hémorragiqueFrance
-
Novartis PharmaceuticalsComplété